Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients
PHASE2CompletedINTERVENTIONAL
Enrollment
15
Participants
Timeline
Start Date
August 31, 2006
Primary Completion Date
July 31, 2011
Study Completion Date
July 31, 2011
Conditions
Adenocarcinoma of the PancreasPancreatic CancerRecurrent Pancreatic CancerStage II Pancreatic CancerStage III Pancreatic CancerStage IV Pancreatic Cancer
Interventions
DRUG
eribulin mesylate
Given IV
Trial Locations (1)
M5G 2M9
University Health Network-Princess Margaret Hospital, Toronto
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00383760 - Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients | Biotech Hunter | Biotech Hunter